Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
- Author(s)
- Changhee Park; Ho Sup Lee; Ka-Won Kang; Won-Sik Lee; Young Rok Do; Jae-Yong Kwak; Ho-Jin Shin; Sung-Yong Kim; Jun Ho Yi; Sung-Nam Lim; Jeong-Ok Lee; Deok-Hwan Yang; Hun Jang; Byoungsan Choi; Jiwoo Lim; Choong Hyun Sun; Ja Min Byun; Sung-Soo Yoon; Youngil Koh
- Keimyung Author(s)
- Do, Young Rok
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Nat Commun
- Issued Date
- 2024
- Volume
- 15
- Abstract
- Potential synergism between Bruton’s tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination of acalabrutinib, lenalidomide and rituximab (R2A) in patients with aggressive relapsed/refractory aggressive (R/R) B-cell non-Hodgkin lymphoma (NHL). The primary endpoint of this study is objective response rate (ORR), and the secondary endpoints are complete remission (CR) rate, duration of response (DoR), progression-free survival (PFS) and overall survival (OS). A total of 66 patients are enrolled mostly with diffuse large B-cell lymphoma. The ORR is 54.5% and CR rate is 31.8% meeting the primary end point. The median DoR is 12.9 months, and 1-year PFS and OS rate is 33.1% and 67.5% respectively. Adverse events (AE) are manageable with the most frequent AE being neutropenia (31.8%). Patients with MYD88 mutations, subtypes known for NF-κB activation, and high BTK expression by immunohistochemistry respond well. Overall, these results show a significant efficacy of the R2A regimen in patients with aggressive R/R B-cell NHL, with exploratory biomarkers suggesting potential associations with response. (ClinicalTrials.gov 51 identifier: NCT04094142)
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.